For Research and Laboratory Use Only
GLP-3(RT) (Glucagon-Like Peptide 3) is a research peptide studied for its role in intestinal growth and mucosal biology. 99% HPLC verified purity with full Certificate of Analysis.
$110.00
$84.99
HPLC tested >99%
Fri, Apr 17 – Sun, Apr 19
For research and laboratory use only. Not for human consumption, therapeutic, or diagnostic use. Must be 21+ to purchase.
WEIGHT LOSS
Phase 3, 68 weeks
RECEPTOR TARGETS
GIP + GLP-1 + Glucagon
WEEKLY INJECTION
Subcutaneous
LIVER FAT REDUCED
Phase 2, 48 weeks
PEOPLE STUDIED
Across all trials
MECHANISM OF ACTION
Unlike GLP-1 (which targets 1 receptor) or GLP-2 (which targets 2), GLP-3 activates three different hormone receptors at once. Each triggers a different metabolic pathway.
Glucose-dependent Insulinotropic Polypeptide
Glucagon-like Peptide-1
From clinical studies and research protocols
Standard escalation protocol used in Phase 2 and Phase 3 trials
2mg once weekly
Starting dose
4mg once weekly
First increase
6mg once weekly
Continued escalation
PHARMACOKINETICS
Once-weekly dosing maintains stable blood levels due to 6-day half-life
No tolerance observed — participants continued losing weight throughout 48-68 week studies
SAFETY PROFILE
FAQ
Retatrutide targets three receptors (GIP, GLP-1, Glucagon) vs one or two. The glucagon receptor may explain the enhanced weight loss (28.7% vs 17% for single-target) and 86% liver fat reduction.
·Research compound — not FDA approved
·Phase 3 clinical trials actively ongoing (TRIUMPH program)
·Gradual dose escalation minimizes side effects
·Developed by Eli Lilly, potential approval ~2027
The "Secret Weapon"
The glucagon receptor is what sets GLP-3 apart. Trial participants saw up to 86% reduction in liver fat.
GLP-1 only
Single target
GLP-1 + GIP
Dual target
GLP-1 + GIP + GCG
Triple target (GLP-3)
CLINICAL / RESEARCH RESULTS
445 adults, 68 weeks, starting weight ~248 lbs. Results announced December 2025.
100%
Lost 5%+
At 12mg dose
58.6%
Lost 25%+
At 12mg dose
39.4%
Lost 30%+
At 12mg dose
RESEARCH APPLICATIONS
86% liver fat reduction, 93% reached normal levels. Directly burns fat stored in liver via glucagon receptor.
Source: Nature Medicine
HbA1c reduced 2.2%, 82% of diabetic participants reached healthy levels. 72% prediabetes reversed.
Source: The Lancet
Triglycerides -38%, LDL -18%, HDL +12%, systolic BP -7 mmHg.
Source: Meta-Analysis 2024
75.8% improvement in pain scores at 12mg dose. 12% became completely pain-free vs 4% placebo.
Source: Clinical Trial Data
9mg or 12mg weekly
Target maintenance dose
·Weekly subcutaneous injection
·Gradual titration helps the body adjust
·Higher starting doses had significantly more nausea
Fatty acid chain (C20 diacid) extends duration of action
Unusual skin sensations like tingling, burning, or numbness. 20.9% at 12mg vs 0.7% placebo. Likely related to glucagon receptor activity.
·Rates are at 12mg dose — lower doses had fewer side effects
·Most GI side effects improve after first 4-8 weeks
·Some participants stopped due to 'perceived excessive weight loss'
COMPOUND INFORMATION
Lyophilized (powder)
Reconstituted
